Chromosomal Changes Predict Clinical Response to Sunitinib in RCC

Article

Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict response to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).

Clinical response can be challenging to predict in some cancers, but new research has shown the ability to predict response to sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC).

Chung-Han Lee, MD, and colleagues were interested in learning more about RCC and why 20% to 30% of patients' tumors become resistant to sunitinib, the first-line therapy for clear cell RCC.

Dr. Lee presented their findings in a poster session (abstract 4552) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29-June 2, 2015 in Chicago. The findings can also be found in the May 2015 online issue of the Journal of Clinical Oncology.1

Their study sought to identify the chromosomal copy number changes that are associated with sunitinib clinical response. Copy number variations are deletions or duplications of a segment of DNA. These variations can involve gains or losses of genomic DNA that are either microscopic or submicroscopic, and may not be visible by standard G-banding karyotyping.Karyotyping is a test to examine chromosomes in a sample of cells, which can help identify genetic problems as the cause of disease.

Whole genome comparative genomic hybridization (aCGH) was performed on pretreatment tumor derived DNA from 76 patients who had been given sunitinib. This process identified differential copy number alterations. Using databases comprising of patients who had not yet been given sunitinib (TCGA-436 and University of Tokyo-240), these alterations were not correlated with overall survival, suggesting that these alterations reflect sunitinib response, and not sunitinib-independent tumor biology.

The researchers concluded that an aCGH analysis of sunitinib-treated clear cell RCC patients revealed multiple novel copy number alterations associated with clinical response. Further study will provide more insight into how exactly sunitinib resistance occurs and how the mechanisms work, but these appear to be positive findings.

 

 

References:

 

 

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content